WO1998056417A1 - Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses - Google Patents
Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses Download PDFInfo
- Publication number
- WO1998056417A1 WO1998056417A1 PCT/US1998/011910 US9811910W WO9856417A1 WO 1998056417 A1 WO1998056417 A1 WO 1998056417A1 US 9811910 W US9811910 W US 9811910W WO 9856417 A1 WO9856417 A1 WO 9856417A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- interrupter
- administered
- agents
- treatment
- rejection
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
Definitions
- This invention relates to the field of tissue transplantation, and more particularly to the use of monoclonal antibodies specific for T cell determinants in blocking cell mediated immune responses resulting in allograft or xeongraft rejection.
- This invention further relates to the prevention or reversal of graft organ rejection and other counter- adaptive T lymphocyte mediated immune responses.
- the invention provides compositions and an order and method of treatment to reduce or prevent the rejection of graft organs in primates or man, and to prevent disease resulting from a poorly targeted T lymphocyte mediated immune response .
- Organ transplantation between genetically non- identical individuals invariably results in immunological rejection of the organ through T cell dependent mechanisms unless that rejection process is bridled by administering drugs that suppress T cell function.
- Both calcineurin phosphatase inhibitors and glucocorticosteroids are used clinically, and both prevent the T cell mediated release of activating cytokines, particularly IL-2. Therapy with these agents is imperfect however. Both act by impairing signaling through the T cell antigen receptor (TCR) , the sole mediator of T cell antigen specificity, and act on all T cells indiscriminately.
- TCR T cell antigen receptor
- the effect of these drugs is not lasting such that cessation of immunosuppression has generally resulted in graft loss even after prolonged rejection free survival.
- transplant recipients must suffer the consequences of non-specific immunosuppression. These consequences include an increased risk of infection and malignancy as well as significant drug related expense and toxicity.
- T cell activation requires both TCR mediated signals and simultaneously delivered costimulatory signals have accumulated over the past 20 years [1] .
- These important costimulatory signals are provided at least in part by the T cell based CD28 molecule when bound to its counter receptors CD80(B7-1) or CD86 (B7-2) , hereafter referred to collectively as B7, on antigen presenting cells (APCs) and perhaps parenchymal cells [1,2,3].
- APCs antigen presenting cells
- CD40L CD154
- CD40L also plays an important role in T cell activation at least in part by up-regulating B7 [4,5] .
- CD40 and CD154 play a fundamental role in establishing T dependent B cell activity [6,7].
- T cell molecule CTLA4 (CD152) , appears to down- regulate costimulation and TCR mediated activation, at least in part by competing with CD28 for B7 and by delivering a unique negative signal to the TCR signal transduction complex [8] .
- an object of this invention is a combination of drugs to prevent rejection of transplanted cells, tissues, or organs from either an allogeneic or a xenogeneic source by administering agents that interfere with T cell costimulatory signaling via CD28 when given in conjunction with agents that interfere with the CD40:CD154 interaction.
- Another object is a method of treatment to reverse ongoing organ rejection by administering agents that interfere with T cell costimulatory signaling via CD28 when given in conjunction with agents that interfere with the CD40:CD154 interaction.
- a third object recognizes that reversal of an ongoing rejection process can be stopped by administering agents that interfere with T cell costimulatory signaling via CD28 when given in conjunction with agents that interfere with the CD40.CD154 interaction.
- a fourth object is that for patients currently being treated with standard immunosuppressive therapies (e.g. glucocorticoids, calcineurin phosphatase inhibitors, mycophenolate mofetil) to prevent the rejection of a transplant or to prevent graft versus host disease, those toxic and expensive medications could be discontinued and replaced with short course therapy with agents that interfere with T cell costimulatory signaling via CD28 when given in conjunction with agents that interfere with the CD40:CD154 interaction.
- standard immunosuppressive therapies e.g. glucocorticoids, calcineurin phosphatase inhibitors, mycophenolate mofetil
- a fifth object is that for patients with a transplanted organ undergoing chronic rejection, agents that interfere with T cell costimulatory signaling via CD28 when given in conjunction with agents that interfere with the CD40:CD154 interaction can block this undesired immune reaction.
- a sixth and most general object is to prevent and/or treat disease states resulting from a counter- adaptive immune response such as the various T- lymphocyte mediated autoimmune illnesses (e.g. insulin dependent diabetes mellitus, multiple sclerosis, etc.) and the various allergic disease states (e.g. hay fever) .
- T- lymphocyte mediated autoimmune illnesses e.g. insulin dependent diabetes mellitus, multiple sclerosis, etc.
- allergic disease states e.g. hay fever
- a seventh object is to test the hypothesis that CTLA4-Ig and the anti-human CD154 specific monoclonal antibody are capable of inducing tolerance to allografted or even xenografted tissues in humans, and in a more general sense to ameliorate (prevent or treat) all counter-adaptive T-lymphocyte mediated disease states.
- agents that interfere with the interaction of the CD28 and/or CD152 CTL4
- their B7 family ligands CD80 and/or CD86
- agents that interfere with the interaction of CD40 and CD154 CD40L
- These agents will be administered parenterally (intramuscularly, subcutaneously, or most preferably intravenously) in a standard pharmaceutical carrier (i.e. iv infusion with saline, water, or other buffer) .
- Agents will be administered after cells, tissue (s), or organ (s) have been transplanted. Initial dosing will be administered as soon as the graft is transplanted at a dose of between 5-20 mg/kg body weight (each agent) . Doses will then be administered on days 2,4,6,8,12,16, and 28 post transplant. Thereafter, should signs of immune rejection ensue, dosing will be repeated to reverse the rejection episode. During this retreatment, dosing will be administered as per the initial induction therapy post transplan .
- This therapy employing agents that interfere with the interaction of both CD28/CD152 :B7 and CD40:CD154 will also be administered to individuals with signs indicating that they are developing a disease (including chronic rejection) , or that are already suffering with an illness, mediated completely or in part by activated T cells (including patients with a transplant currently receiving standard immunosuppressive therapy) .
- Such "counter-adaptive" T cell responses also include diseases like the various autoimmune illnesses (for example insulin dependent diabetes mellitus, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, and systemic lupus erythematosus) as well as in states resulting from the sequela of an immune response like allergic illnesses (hay fever) .
- the therapy will be administered in doses ranging from 2-20 mg/kg body weight (each agent) as frequently as every other day for up to 28 days.
- treatment package will be termed “immune reeducation” and will consist of the drugs to be administered, the carrier solvent for those agents, and the infusion system to be used to administer the agent.
- CTLA4-Ig and anti-CD154 were tested alone and in combination on rhesus peripheral blood leukocytes in vitro, and in rhesus monkeys transplanted with primarily vascularized renal allografts.
- Fig. 2 (A) Survival and renal function as determined by serum creatinine following unmodified allogeneic renal transplantation (dashes) or transplantation following induction with CTI_A4-Ig alone (squares) or humanized anti-human CD154 alone (diamonds) . Open arrows indicate retreatment during biopsy proven rejection. Solid arrows continued survival. (B) Survival and renal function as determined by serum creatinine following unmodified allogenic renal transplantation (dashes) or transplantation following induction with both CTLA4-Ig and humanized anti-human CD154. Open circles indicate treatment on days 0,2,4,6,8,10, and 12 post-transplant . Closed circles indicate treatment on days 0,2,4,6,8,12,16, and 28 post-transplant . Open arrows indicate retreatment during biopsy proven rejection for the animal depicted in open circles. Solid arrows indicate continued survival free of rejection since transplantation.
- Fig. 3. (A) Renal allograft histology showing acute cellular rejection following unmodified renal allotransplantation in rhesus monkeys. (B) Renal allograft histology showing acute cellular rejection prior to reversal with humanized anti-human CD154. (C) Normal renal allograft histology from an animal with normal renal function 163 days following transplantation and induction with CTLA4-Ig and humanized anti-human CD154. (D) A perivascular lymphoid aggregate with the allograft shown in C. These nests of lymphocytes exist in the allograft despite normal function and the absence of immunosuppression. All micrographs are 250x.
- Fig. 4 Mixed lymphocyte responses against donor lymphocytes and third party lymphocytes for two rhesus monkeys 150 days after allotransplantation with rejection free survival and normal renal function and without any chronic therapy. Both donor and third party responsiveness is maintained.
- skin grafts placed on a rhesus monkey 6 months following successful allotransplantation revealed donor specific tolerance. Three skin grafts were placed: one from the host (an autograft to control for surgical technique) , one from the allogeneic kidney donor, and one from a third party donor. Only the third party donor skin was rejected at day 14 (and counting) since the grafting. This data indicates that functional donor specific tolerance has been achieved despite failure of the allo-MLR to reflect it.
- the invention is applicable to both xeno- and allo- transplants, and for more general application to disease states resulting from counter-adaptive T- lymphocyte responses.
- the invention comprises a composition involving the parenteral administration for an agent interfering with the T cell costimulatory receptors' (CD28/CD152) ability to bind with B7 in close time sequence to administration of an agent preventing signaling through CD152.
- CTLA4-Ig provides insurance against B7 expression that escapes the effects of humanized anti-human CD154. In that instance, considerable time seems to be required to mount an effective acute rejection with the few cells that escape initial blockade.
- the rhesus monkey model used in this study has been shown repeatedly to be a rigorous test of immune manipulation - one that isakily sensitive to even minor changes in allograft function or adverse effects on recipient wound healing and immune function [13,15,19].
- it has obvious biological similarity to human renal transplantation. Specifically, genes that encode MHC proteins are well conversed between rhesus monkeys and humans [20-22] , and their rejection of vascularized organs closely parallel that seen clinically [13,15,19]. Nevertheless, issues of optimal dosing and treatment time course remain to be resolved.
- Human CTLA4-Ig and a control fusion protein-IgGl were prepared as previously described [2] and shipped in solution by Genetics Institute, Cambridge, MA.
- the anti-CD40 ligand antibody humanized anti-human CD154 was prepared as previously described [6,7] and shipped in solution by Biogen Corporation, Cambridge, MA.
- the hamster anti-mouse CD28 monoclonal antibody PV-1 (IgGl, clone G62) was purified from hybridoma culture supernatants and used as in isotype control monoclonal antibody.
- Donor-recipient combinations and animals chosen for third party cells were selected based on genetic non-identity at both MHC class I and class II.
- Class I disparity was established by one-dimensional isoelectric focusing as previously described [13] .
- Class II disparity was established based on the results of unidirectional mixed lymphocyte reactions (MLRs) .
- MLRs mixed lymphocyte reactions
- the animal's DRB loci were verified to be disparate by denaturing gradient gel electrophoresis and direct sequencing of the second exon of DRB as previously described [14] . Vigorous in vitro T cell responsiveness of the recipient towards the donor was confirmed in vitro for all donor-recipient pairs.
- the experiments described in this study were conducted according to the principles set forth in the "Guide for the Care and Use of Laboratory Animals" Institute of Laboratory Animals Resources, National Research Council, DHHS, Pub. No. (NIH) 86-23 (19850) .
- Unidirectional MLRs were performed on all animals prior to transplantation and on rejection free survivors after 100 days. Each animal was tested against all potential donors to establish the highest responder pairs for transplantation.
- Responder cells (3 x 10 5 ) were incubated with irradiated stimulator cells (1 x 10 s ) at 37°C for 5 days. Cells were pulse- labeled with 3 H-thymidine and proliferation was monitored by 3 H-thymidine incorporation.
- Polyclonal stimulation with Concanavilin A 25 mcg/ml served as a positive control. A stimulation index was calculated by normalization to self reactivity, which in all cases was near background incorporation.
- CTLA4-Ig or humanized anti-human CD154 was added to the MLR on day 1 at concentrations ranging from 100 mcg/ml to 0.01 mcg/ml. Combined treatments were performed by varying the CTLA4-Ig concentration and holding the humanized anti-human CD154 concentration steady at 50 mcg/ml.
- Peripheral blood lymphocyte phenotype analysis was performed prior to transplantation and periodically during and after drug therapy. Assays evaluated 0.2 ml of heparinized whole blood diluted with phosphate buffered saline and 1% fetal calf serum. FITC labeled Til, Bl (Coulter) , and FN18 (the generous gift of Dr.
- CD2 T cell/NK cell
- CD20 B cell
- CD3 T cell positive cells respectively.
- Red blood cells were removed from the preparation by ACK lysis buffer (0.15 M NH 4 C1, 1.0 mM KHC0 3 , 0.1 mM Na 2 EDTA, pH 7.3) treatment following staining.
- Cells were subjected to flow cytometry immediately, or following fixation in 1% paraformaldehyde . Flow cytometry was performed using a Becton Dickinson FACSCAN.
- Renal allotransplantation was performed as previously described [13] . Briefly, outbred juvenile (1-3 years of age) rhesus monkeys, seronegative for simian immunodeficiency virus, simian retrovirus, and herpes B virus, were obtained from the Primate Center (University of Wisconsin) or LABS (Yemassee, SC) . Procedures were performed under general anesthesia using ketamine (1 mg/kg, i.m.), xylazine (1 mg/kg, i.m.) and halothane (1%, inhaled). Transplantation was performed between genetically distinct donor-recipient pairs as determined by the MHC analysis described above.
- the animals were heparinized during organ harvest and implantation (100 units/kg) .
- the allograft was implanted using standard microvascular techniques to create an end to side anastamosis between the donor renal artery and recipient distal aorta as well as the donor renal vein and recipient vena cava. A primary ureteroneocystostomy was then created. Bilateral native nephrectomy was completed prior to closure. Animals were treated with intravenous fluid for approximately 36 hours until oral intake was adequate. Trimethaprim-sulfa was administered for 3 days for surgical antibiotic prophylaxis. Each animal received 81 mg of aspirin on the day of surgery.
- Biopsies were performed on animals suspected of having rejection using a 20-gauge needle core device (Biopty-Cut, Bard) . Standard staining with hematoxylin and eosin was performed on frozen or formalin fixed tissue to confirm the diagnosis of rejection. Animals were euthanized at the time of anuria or if a weight loss of 15% of pre-transplant body weight occurred in accordance with AAALAC standards. All animals underwent complete gross and histopathological evaluation at the time of death.
- CTLA4-Ig and humanized anti-human CD154 inhibited rhesus MLRs in a dose dependent fashion (Fig. 1) .
- CTLA4-Ig was, however, more effective than humanized anti-human CD154 as a single agent in preventing T cell proliferation.
- Substantial reduction in thymidine incorporation was seen at a CTLA4-Ig concentration of 0.1 mcg/ml, and further inhibition was achieved at higher concentrations.
- Modest reduction in proliferation was achieved with humanized anti-human CD154 concentrations of 0.01 mcg/ml but inhibition was not substantially improved by increasing concentrations. Both agents acted synergistically, the combination inhibiting proliferation approximately 100 times more effectively than either agent alone did.
- graft loss was due to cellular rejection indistinguishable from that seen in the control animals.
- One animal was treated with CTLA4-Ig 20 mg/kg on the day of transplantation followed by a 12 day course of 10 mg/kg every other day and had graft survival prolonged to 30 days ⁇ Fig. 2A) ⁇ .
- graft loss was due to acute cellular rejection.
- Extrapolating from previously published work in the rat heterotopic cardiac allograft model of Turka, et al [9] a donor specific transfusion of lymph node derived lymphocytes (10 8 ) was given at the time of transplantation to this 2 animals.
- Fig. 2A Two animals were treated with humanized anti-human CD154 alone (Fig. 2A) . Both animals received 20 mg/kg every other day beginning on the day of surgery and continuing for 14 post-operative days (8 doses total) . Both animals experienced extended rejection free survival, although transient creatinine elevations were recorded during the second and fourth post-operative weeks. Both animals rejected between 95 and 100 days post -transplant . Biopsy was performed on each animal to confirm the diagnosis (Fig. 3B) . Both animals were then retreated with 7 doses of humanized anti -human CD154 (20 mg/kg; one animal every other day and one animal daily) and both returned to normal graft function with no demonstrable adverse effects. They remain alive and well greater than 150 days__ after transplantation at the time of this writing.
- both of these animals had transient increases in their creatinine combined with an increase in graft size during the fourth pos -operative week. It was hypothesized that this graft swelling reflected a second wave of infiltrating lymphocytes and therefore led to a modified dosage schedule such that both reagents were given on the day of surgery and on postoperative days 2,4,6,8, 12, 16, and 28. Two animals were treated with this modified regimen (Fig. 2B) . Both have experienced rejection free survival, free of illness or alterations in renal function for greater than 150 days. Both remain alive and well at the time of this writing. After 100 days of rejection free survival, MLRs were repeated against donor cells and third party cells.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP50308699A JP2002504120A (en) | 1997-06-11 | 1998-06-10 | Compositions and methods for preventing graft rejection and anti-adaptive T lymphocyte mediated immune response |
AU79567/98A AU748533B2 (en) | 1997-06-11 | 1998-06-10 | Composition and method to prevent graft rejection and other counter-adaptive T lymphocyte mediated immune responses |
CA002291338A CA2291338A1 (en) | 1997-06-11 | 1998-06-10 | Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses |
IL13307098A IL133070A0 (en) | 1997-06-11 | 1998-06-10 | Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses |
EP98930097A EP1009432A4 (en) | 1997-06-11 | 1998-06-10 | Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4938997P | 1997-06-11 | 1997-06-11 | |
US60/049,389 | 1997-06-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998056417A1 true WO1998056417A1 (en) | 1998-12-17 |
Family
ID=21959563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/011910 WO1998056417A1 (en) | 1997-06-11 | 1998-06-10 | Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1009432A4 (en) |
JP (1) | JP2002504120A (en) |
AU (1) | AU748533B2 (en) |
CA (1) | CA2291338A1 (en) |
IL (1) | IL133070A0 (en) |
WO (1) | WO1998056417A1 (en) |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000040270A2 (en) * | 1999-01-08 | 2000-07-13 | Wisconsin Alumni Research Foundation | Methods of prolonging transplant survival using immunotoxins and costimulation blockade of cd154 and cd28 |
WO2001054732A1 (en) * | 2000-01-27 | 2001-08-02 | Genetics Institute, Llc. | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
WO2001095928A2 (en) | 2000-06-09 | 2001-12-20 | Bristol-Myers Squibb Company | Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion |
EP1241249A1 (en) * | 2001-03-12 | 2002-09-18 | Gerold Schuler | CD4+CD25+regulatory T cells from human blood |
JP2002533118A (en) * | 1998-12-29 | 2002-10-08 | ユニバーシティ オブ バーモント アンド ステイト アグリカルチャー カレッジ | Use of CD40 engagement to modify T cell receptor use |
WO2002060485A3 (en) * | 2001-01-31 | 2003-06-05 | Idec Pharma Corp | Use of immunoregulatory antibodies in the treatment of neoplastic disorders |
US6797263B2 (en) | 2000-05-12 | 2004-09-28 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for achieving immune suppression |
US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
US7105166B1 (en) | 1991-06-27 | 2006-09-12 | Bristol-Myers Squibb Company | Soluble CTLA4 mutant molecules and uses thereof |
US7304033B2 (en) | 2001-05-23 | 2007-12-04 | Bristol-Myers Squibb Company | Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules |
US7455835B2 (en) | 2000-07-03 | 2008-11-25 | Bristol-Myers Squibb Company | Methods for treating immune system diseases using a soluble CTLA4 molecule |
WO2010023482A2 (en) * | 2008-08-29 | 2010-03-04 | Isis Innovation Ltd | Therapeutic antibody |
US8076134B2 (en) | 2002-08-12 | 2011-12-13 | Argos Therapeutics, Inc. | CD4+CD25− T cells and Tr1-like regulatory T cells |
US8148332B2 (en) | 2000-07-03 | 2012-04-03 | Bristol-Myers Squibb Company | Method for treating a rheumatic disease using a soluble TLA4 molecule |
US10006901B2 (en) | 2001-03-12 | 2018-06-26 | Argos Therapeutics, Inc. | CD4+CD25+ regulatory T cells from human blood |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2019245038A1 (en) | 2018-06-22 | 2021-07-08 | 株式会社Junten Bio | Antibodies that induce immune tolerance and induced lymphocytes using a cell mixture having a complex state, and cell therapeutic agents and therapeutic methods that use induced lymphocytes. |
US20210269529A1 (en) | 2018-06-22 | 2021-09-02 | Junten Bio Co., Ltd. | Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte |
TWI832868B (en) | 2018-06-22 | 2024-02-21 | 日商順天生化股份有限公司 | Compositions for inducing infectious immune tolerance |
WO2023153388A1 (en) * | 2022-02-08 | 2023-08-17 | 学校法人順天堂 | Allotransplantation method and rejection rpeventing method |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995034320A2 (en) * | 1994-06-07 | 1995-12-21 | Regents Of The University Of Minnesota | Methods for inhibiting antigen specific t cell responses |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK0892643T4 (en) * | 1996-03-20 | 2009-12-14 | Bristol Myers Squibb Co | Methods for inhibiting an immune response by blocking the GP39 / CD40 and CTLA4 / CD28 / B7 pathways and preparations for use therewith |
-
1998
- 1998-06-10 AU AU79567/98A patent/AU748533B2/en not_active Ceased
- 1998-06-10 JP JP50308699A patent/JP2002504120A/en active Pending
- 1998-06-10 WO PCT/US1998/011910 patent/WO1998056417A1/en not_active Application Discontinuation
- 1998-06-10 CA CA002291338A patent/CA2291338A1/en not_active Abandoned
- 1998-06-10 EP EP98930097A patent/EP1009432A4/en not_active Withdrawn
- 1998-06-10 IL IL13307098A patent/IL133070A0/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995034320A2 (en) * | 1994-06-07 | 1995-12-21 | Regents Of The University Of Minnesota | Methods for inhibiting antigen specific t cell responses |
Non-Patent Citations (3)
Title |
---|
ELWOOD E. T., ET AL.: "LONG-TERM MURINE SKIN ALLOGRAFT SURVIVAL WITH PERIOPERATIVE CTLA4- IG AND ANTI-GP39: THE ROLE OF CD4+ T CELLS.", SURGICAL FORUM, CHICAGO, US, vol. 47., 1 January 1996 (1996-01-01), US, pages 427 - 429., XP002914296, ISSN: 0071-8041 * |
LARSEN C. P., ET AL.: "LONG-TERM ACCEPTANCE OF SKIN AND CARDIAC ALLOGRAFTS AFTER BLOCKING CD40 AND CD28 PATHWAYS.", NATURE, NATURE PUBLISHING GROUP, UNITED KINGDOM, vol. 381., 30 May 1996 (1996-05-30), United Kingdom, pages 434 - 438., XP002914297, ISSN: 0028-0836, DOI: 10.1038/381434a0 * |
See also references of EP1009432A4 * |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7105166B1 (en) | 1991-06-27 | 2006-09-12 | Bristol-Myers Squibb Company | Soluble CTLA4 mutant molecules and uses thereof |
JP2002533118A (en) * | 1998-12-29 | 2002-10-08 | ユニバーシティ オブ バーモント アンド ステイト アグリカルチャー カレッジ | Use of CD40 engagement to modify T cell receptor use |
WO2000040270A3 (en) * | 1999-01-08 | 2001-10-18 | Wisconsin Alumni Res Found | Methods of prolonging transplant survival using immunotoxins and costimulation blockade of cd154 and cd28 |
WO2000040270A2 (en) * | 1999-01-08 | 2000-07-13 | Wisconsin Alumni Research Foundation | Methods of prolonging transplant survival using immunotoxins and costimulation blockade of cd154 and cd28 |
WO2001054732A1 (en) * | 2000-01-27 | 2001-08-02 | Genetics Institute, Llc. | Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof |
US7034121B2 (en) | 2000-01-27 | 2006-04-25 | Genetics Institue, Llc | Antibodies against CTLA4 |
US6797263B2 (en) | 2000-05-12 | 2004-09-28 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for achieving immune suppression |
US7347995B2 (en) | 2000-05-12 | 2008-03-25 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for achieving immune suppression |
US10370428B2 (en) | 2000-05-26 | 2019-08-06 | Bristol-Myers Squibb Company | Methods of treatment using CTLA4 mutant molecules |
US9758565B2 (en) | 2000-05-26 | 2017-09-12 | Bristol-Myers Squibb Company | Methods of treatment using CTLA4 mutant molecules |
US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
US8785398B2 (en) | 2000-05-26 | 2014-07-22 | Bristol-Myers Squibb Company | Methods of treatment using CTLA4 mutant molecules |
US7700556B2 (en) | 2000-05-26 | 2010-04-20 | Bristol-Myers Squibb Company | Methods of treatment using CTLA4 mutant molecules |
US7439230B2 (en) | 2000-05-26 | 2008-10-21 | Bristol-Myers Squibb Company | Methods of treatment using CTLA4 mutant molecules |
WO2001095928A2 (en) | 2000-06-09 | 2001-12-20 | Bristol-Myers Squibb Company | Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion |
WO2001095928A3 (en) * | 2000-06-09 | 2002-05-30 | Bristol Myers Squibb Co | Methods for regulating a cell-mediated immune response by blocking lymphocytic signals and by blocking lfa-1 mediated adhesion |
JP2004503507A (en) * | 2000-06-09 | 2004-02-05 | ブリストル−マイヤーズ スクイブ カンパニー | Method of modulating a cellular immune response by blocking lymphocyte signals and blocking LFA-1-mediated adhesion |
US7455835B2 (en) | 2000-07-03 | 2008-11-25 | Bristol-Myers Squibb Company | Methods for treating immune system diseases using a soluble CTLA4 molecule |
US8722632B2 (en) | 2000-07-03 | 2014-05-13 | Bristol-Myers Squibb Company | Methods for treating Sjogrens syndrome by administering a soluble CTLA4 molecule |
US10052360B2 (en) | 2000-07-03 | 2018-08-21 | Bristol-Myers Squibb Company | Methods for treating dermatomyositis or polymyositis by administering a soluble CTLA4 molecule |
US8703718B2 (en) | 2000-07-03 | 2014-04-22 | Bristol-Myers Squibb Company | Methods for treating juvenile rheumatoid arthritis by administering a soluble CTLA4 molecule |
US8148332B2 (en) | 2000-07-03 | 2012-04-03 | Bristol-Myers Squibb Company | Method for treating a rheumatic disease using a soluble TLA4 molecule |
US8227420B2 (en) | 2000-07-03 | 2012-07-24 | Bristol-Myers Squibb Company | Method for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
US8497247B2 (en) | 2000-07-03 | 2013-07-30 | Bristol-Myers Squibb Company | Methods for treating type I diabetes mellitus by administering a soluble CTLA4 molecule |
US9296808B2 (en) | 2000-07-03 | 2016-03-29 | Bristol-Myers Squibb Company | Methods for treating scleroderma by administering a soluble CTLA4 molecule |
WO2002060485A3 (en) * | 2001-01-31 | 2003-06-05 | Idec Pharma Corp | Use of immunoregulatory antibodies in the treatment of neoplastic disorders |
EP1241249A1 (en) * | 2001-03-12 | 2002-09-18 | Gerold Schuler | CD4+CD25+regulatory T cells from human blood |
US10006901B2 (en) | 2001-03-12 | 2018-06-26 | Argos Therapeutics, Inc. | CD4+CD25+ regulatory T cells from human blood |
WO2002072799A1 (en) * | 2001-03-12 | 2002-09-19 | Merix Bioscience Inc. | Cd4+cd25+ regulatory t cells from human blood |
US7304033B2 (en) | 2001-05-23 | 2007-12-04 | Bristol-Myers Squibb Company | Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules |
US7829534B2 (en) | 2001-05-23 | 2010-11-09 | Bristol-Myers Squibb Company | Methods for protecting allogeneic islet transplant using soluble CTLA4 mutant molecules |
US8603815B2 (en) | 2002-08-12 | 2013-12-10 | Argos Therapeutics, Inc. | CD4+ CD25− T cells and Tr1-like regulatory T cells |
US8222033B2 (en) | 2002-08-12 | 2012-07-17 | Argos Therapeutics, Inc. | CD4+CD25− T cells and Tr1-like regulatory T cells |
US8076134B2 (en) | 2002-08-12 | 2011-12-13 | Argos Therapeutics, Inc. | CD4+CD25− T cells and Tr1-like regulatory T cells |
WO2010023482A3 (en) * | 2008-08-29 | 2010-06-24 | Isis Innovation Ltd | Therapeutic antibody |
WO2010023482A2 (en) * | 2008-08-29 | 2010-03-04 | Isis Innovation Ltd | Therapeutic antibody |
Also Published As
Publication number | Publication date |
---|---|
AU748533B2 (en) | 2002-06-06 |
AU7956798A (en) | 1998-12-30 |
EP1009432A4 (en) | 2004-07-07 |
CA2291338A1 (en) | 1998-12-17 |
IL133070A0 (en) | 2001-03-19 |
EP1009432A1 (en) | 2000-06-21 |
JP2002504120A (en) | 2002-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU735592B2 (en) | Use of a CD40:CD154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection | |
AU748533B2 (en) | Composition and method to prevent graft rejection and other counter-adaptive T lymphocyte mediated immune responses | |
Kirk et al. | CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates | |
Blaha et al. | The influence of immunosuppressive drugs on tolerance induction through bone marrow transplantation with costimulation blockade | |
Rossini et al. | Induction of immunologic tolerance for transplantation | |
US5783216A (en) | Methods for inhibiting rejection of transplanted tissue | |
JP2002502823A (en) | Costimulation blockade and mixed chimerism in transplantation | |
EP0621786B1 (en) | Induced tolerance to xenografts | |
Quesenberry et al. | Allogeneic chimerism with low-dose irradiation, antigen presensitization, and costimulator blockade in H-2 mismatched mice | |
KR0183029B1 (en) | Monoclonal antibodies for inducing tolerance | |
BG64976B1 (en) | Cd154 blockade therapty in tissue transplantation of pancreatic isles | |
US6290955B1 (en) | Antibodies against T cells as therapeutics | |
Metzler et al. | Combinations of anti-LFA-1, everolimus, anti-CD40 ligand, and allogeneic bone marrow induce central transplantation tolerance through hemopoietic chimerism, including protection from chronic heart allograft rejection | |
MXPA99010893A (en) | Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses | |
Li et al. | CTLA4-Ig-based conditioning regimen to induce tolerance to cardiac allografts | |
EP0697876B1 (en) | Xenograft thymus | |
CN1736483A (en) | Use of a CD40:CD154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection | |
MXPA99010571A (en) | Use of a cd40:cd154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection | |
CZ403599A3 (en) | Use of agent breaking CD40:CD154 bond for preparing a medicament inhibiting rejection of tissue graft and preparation in which said agent breaking CD40:CD154 bond is comprised | |
Bartlett et al. | Co-stimulatory blockade and tolerance induction in transplantation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 133070 Country of ref document: IL |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 501201 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 79567/98 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2291338 Country of ref document: CA Ref country code: CA Ref document number: 2291338 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1999/010893 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998930097 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1998930097 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 79567/98 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998930097 Country of ref document: EP |